Navigation Links
Generex Announces Details of Investor Conference Call

WORCESTER, Mass. and TORONTO, Jan. 29, 2013 /PRNewswire/ -- Generex Biotechnology Corporation ( (OTCBB: GNBT) previously announced that Company management has scheduled an investor conference call for Thursday, January 31, 2013.

Today, the Company provided the following information for access to the conference call:

Date of Call:    Thursday, January 31, 2013

Time of Call:   10 a.m. EST

Participant Operator Assisted Toll-Free Dial-In Number: (877) 312-5845

Participant Operator Assisted International Dial-In Number: (970) 315-0470

The purpose of the call is to provide the Company's stockholders with a review of recent Company activity and management's go-forward plans.  The discussion will include:  the clinical and regulatory status of the AE37 breast cancer vaccine and business development initiatives; the clinical and regulatory status of the Generex Oral-lyn™ buccal insulin spray product; the status of the proposed spinout of Antigen Express; Company finances; and, the annual and special meeting of the Company's stockholders (scheduled for March 28, 2013).

Participating in the call on behalf of the Company will be:

  • Mark Fletcher , President & Chief Executive Officer
  • John Barratt , Chairman of the Board
  • Dr. Eric von Hofe , President of Antigen Express, Inc.
  • Dr. James H. Anderson, Jr. , Director and Senior Scientific Advisor
  • Dr. David Brusegard , Chief Operating Officer

Company stockholders are invited to phone in questions and comments for the management team.  Audio replay of the call will be available on the Generex website following the call.

About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation technologies in immunotherapy. One focuses on modification of peptides with Ii-Key to increase potency while a second relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at or the Antigen Express website at

Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Addresses Recent Trading Volume in Shares of its Common Stock
2. Generex Announces Results of Annual Stockholders Meeting
3. Generex Announces Interviews Featuring the Antigen Express AE37 Breast Cancer Vaccine at ASCO 2012
4. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
5. Generex Augments Antigen Express Scientific Advisory Board
6. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
7. Generex Announces Presentations of Antigen Express AE37 Breast Cancer Vaccine Data at ASCO 2012
8. Amedica Announces Expansion Of Executive Team
9. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
10. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
11. Medisafe 1 Technologies Announces the Ex-Dividend Date on April 30 2013, Record Date on May 3 2013 and the Payment Date on May 6 2013
Post Your Comments:
(Date:11/30/2015)... and SAN DIEGO , Nov. ... Inc. (NASDAQ: ARNA ) today announced that the ... filing the New Drug Application (NDA) for an extended ... formulation will offer patients a chronic weight management treatment ... ) is currently approved as an adjunct to a ...
(Date:11/30/2015)... ST. LOUIS , Nov. 30, 2015  Premera ... today announced an early renewal of the companies, long-standing ... will now extend through at least 2019. ... pharmacy benefit manager capabilities during a competitive review and ... offer the best health plan integration and deliver the ...
(Date:11/30/2015)... N.H. , Nov. 30, 2015 ... that it will feature its latest solutions for ... early identification of cancer at the Radiological Society ... Chicago from November 29 ... recent product advances including iReveal®, an automated breast ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb ... the leading plastic surgery practices in Florida, is proud to announce that Dr. ... surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is ...
(Date:11/30/2015)... ... November 30, 2015 , ... The successful filing of an Investigational New Drug ... so important to this key industry segment, Regis Technologies has decided to sponsor and ... 4th at 11am EST. , Federal law does not allow new drugs to cross ...
(Date:11/30/2015)... ... November 30, 2015 , ... Healthjump, Inc. ... Inc., a Healthcare IT consulting, development and support company. The purchase will expand ... available within DataTrade to extend the services currently provided by Healthjump. ...
(Date:11/30/2015)... ... November 30, 2015 , ... GKhair & Tibolli team members and artists were ... held on November 8th and 9th at the Puerto Rico Convention Center, San Juan ... beauticians and top of the line fashion journalists. The San Juan Beauty Show carries ...
(Date:11/30/2015)... ... 2015 , ... Innovaacom, a leading provider of medical education ... of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, Asia, ... online and face-to-face education for pharmacists who are fast becoming the new “gatekeepers” ...
Breaking Medicine News(10 mins):